Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 3;100(11):adv00143.
doi: 10.2340/00015555-3498.

Update of the Management of Cutaneous Squamous-cell Carcinoma

Review

Update of the Management of Cutaneous Squamous-cell Carcinoma

Eve Maubec. Acta Derm Venereol. .

Abstract

For all primary cutaneous squamous cell carcinomas (cSCCs), physical examination should include full skin examination, recording of tumour diameter and regional lymph-node-basin status. Surgery is the treatment of choice, with a minimal 5-mm margin. For elderly patients with well-differentiated tumours, other surgical modalities can be explored. Surgery for organ-transplant recipients should not be delayed. The issue with cSCC is identifying high-risk tumours with staging, as this may alter treatment and follow-up schedules. Adjuvant radiation therapy should be considered for incomplete resection, when re-excision is impossible or there are poor-prognosis histological findings. Recommendations are biannual dermatological surveillance for at least 2 years, but in elderly patients with small, well-differentiated tumours long-term follow-up is not always necessary. In case of positive lymph nodes, radical dissection is needed, with optional regional postoperative adjuvant radiation. Advanced cSCCs are defined as unresectable local, regional or distant disease requiring systemic treatment. Their only approved treatment is the PD-1 inhibitor, cemiplimab. Trials evaluating adjuvant or neo-adjuvant anti-PD-1 are ongoing. Platin-based chemo or anti-EGFR therapies are possible second-line treatments. For transplant patients, minimizing immunosuppression and switching to sirolimus must be considered at first appearance of cSCC.

Keywords: adjuvant treatment; anti-PD-1; cutaneous squamous cell carcinoma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cutaneous squamous cell carcinoma – staging criteria. (a) American Joint Committee on Cancer 8th edition staging of head-and-neck tumours (adapted from (11). (b) Brigham and Women’s Hospital tumour-staging items (adapted from (17)).
Fig. 2
Fig. 2
The different types of advanced cutaneous squamous cell carcinomas. Local disease (left): local unresectable disease without regional or distant disease. Regional disease (top right): at least regional unresectable disease without distant disease. Distant disease (bottom right): at least one unresectable distant metastasis.

References

    1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015; 151: 1081–1086. - PubMed
    1. Wassberg C, Thorn M, Johansson AM, Bergstrom R, Berne B, Ringborg U. Increasing incidence rates of squamous cell carcinoma of the skin in Sweden. Acta Derm Venereol 2001; 81: 268–272. - PubMed
    1. Dal H, Boldemann C, Lindelof B. Trends during a half century in relative squamous cell carcinoma distribution by body site in the Swedish population: support for accumulated sun exposure as the main risk factor. J Dermatol 2008; 35: 55–62. - PubMed
    1. Schmitt J, Seidler A, Diepgen TL, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 2011; 164: 291–307. - PubMed
    1. Christensen GB, Ingvar C, Hartman LW, Olsson H, Nielsen K. Sunbed use increases cutaneous squamous cell carcinoma risk in women: a large-scale, prospective study in Sweden. Acta Derm Venereol 2019; 99: 878–883. - PubMed

MeSH terms

Substances